SciELO - Scientific Electronic Library Online

vol.41 número6Avaliação da resposta imune humoral frente a antígenos de Strongyloides venezuelensisRegistro de Culicidae de importância epidemiológica na área rural de Manaus, Amazonas índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados


Revista da Sociedade Brasileira de Medicina Tropical

versão impressa ISSN 0037-8682versão On-line ISSN 1678-9849


FANTE, Camila Argenta; DIETERISH, Solange  e  RODRIGUEZ, Rubens. Betamethasone and aqueous extract of Arctium lappa for treating angiostrongyliasis. Rev. Soc. Bras. Med. Trop. [online]. 2008, vol.41, n.6, pp.654-657. ISSN 0037-8682.

Angiostrongylus costaricensis is a parasite that causes abdominal angiostrongyliasis in humans. The treatment for it includes the use of anti-inflammatory drugs, despite the lack of studies to justify this approach. The objective of this paper was to evaluate the effect of betamethasone and Arctium lappa on the evolution of intestinal lesions induced by this parasite. Adult male Swiss mice were used, distributed into four groups: infected and treated with betamethasone; infected and treated with Arctium lappa; infected and not treated; and control group. The treatments were started on the 15th day after infection and continued for 15 days. The presence of eosinophilic infiltration and granuloma was evaluated (1-mild; 2-moderate; 3-severe). Betamethasone allowed the lesions to evolve into more severe forms, while the extract did not interfere with disease progression. The substances applied were ineffective for protection against the lesions induced by Angiostrongylus costaricensis in mice. These findings discourage the use of betamethasone and Arctium lappa for humans affected by abdominal angiostrongyliasis.

Palavras-chave : Angiostrongyliasis; Anti-inflammatory drugs; Betamethasone; Arctium lappa.

        · resumo em Português     · texto em Português     · Português ( pdf epdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons